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ABSTRACT We have analyzed a pair of human myeloma
immunoglobulins (biclonal proteins) of the IgG and IgA
classes from a single patient, GR. The light chains are identi-
cal in amino-acid sequence over 40 residues at their NHrter-
minus, whereas the heavy chains are identical throughout 45
residues of their NH2-terminus. Additional chemical and
serological studies suggest the light chains and variable re-
gions of the heavy chain (VH) are very similar, if not identi-
cal. The implications of these and of other published studies
are discussed with regard to (I) the association of one VH re-
gion with multiple constant regions of the heavy chain (CH
regions), (ii) two alternative types of V-C joining mecha-
nisms, -(ii) the differentiation of antibody-producing cells,
and (iv) three categories of biclonal immunoglobulins.
Structural and organizational features of antibody molecules
and genes have provided fascinating insights into the molec-
ular nature of differentiation as it must occur in antibody-
producing cells (B-cells) (1, 2). The antibody molecule is
comprised of two types of polypeptides, light (L) and heavy
(H) chains. All antibody polypeptides can be divided into an
NH2-terminal variable (V) region and a COOH-terminal
constant (C) region. The amino-acid sequence of the C re-
gion of the heavy chain (CH region) determines the class of
the immunoglobulin molecule (e.g., IgM, IgG, IgA, IgD, or
IgE). Comparative analyses of the variable regions of light
and heavy chains demonstrate three and four segments, re-
spectively, of extreme amino-acid sequence variability,
termed hypervariable regions. Five of these hypervariable
regions fold to comprise the walls of the antigen-binding
crevice. Three families of genes code for antibody mole-
cules, two for light chains (X and K) and a third for heavy
chains. The variable and constant regions in each family are
coded by distinct genes. Thus, each immunoglobulin chain
appears to be coded by two distinct genes (a variable and a
constant gene) which are probably joined at the DNA level
during the differentiation of each antibody-producing cell.
Accordingly, four decisions must be made with respect to
the antibody genes during differentiation; that is, individual
VL, VH, CL, and CH genes must be expressed.
Antibody-producing cells, like other eukaryotic cells, have
a discrete pathway of differentiation. In the mammalian
fetus, stem cells for hematopoietic (blood) cells appear first
in the yolk sac and then migrate to the liver and the bone
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marrow as some differentiate into lymphocytes (3, 4). As the
animal matures, lymphocytes migrate to the peripheral lym-
phoid organs (spleen and lymph nodes) where they undergo
their final differentiation steps upon contact with antigen.
This process produces plasma cells which are specialized to
produce thousands of antibody molecules per second and
memory cells which are responsible for the enhanced secon-
dary immune response.
In molecular terms three generalizations are commonly
accepted about the differentiation of antibody-producing
cells (see ref. 5). (i) All the antibody molecules on a particu-
lar lymphocyte have the same specificity (i.e., same VL and
VH regions). (ii) Early in the differentiation cycle of lym-
phocytes the antibody receptor is an IgM molecule. Some-
what later IgM and IgD molecules, both potential receptors,
may be expressed on the cell surface. (iii) Finally, individual
lymphocytes may "switch" from the synthesis of IgM (and
IgD) to IgG, IgA, or IgE.
Rare cancerous or neoplastic transformations can appar-
ently occur at any stage in the differentiation of antibody-
producing cells (2). Chronic lymphocytic leukemia and
Burkitt's lymphoma involve B lymphocytes at an early stage
of differentiation. The macroglobulinemia of Waldenstr6m
represents an accumulation of cells in transition from B lym-
phocytes to mature antibody-producing cells. Multiple mye-
loma results in the neoplastic proliferation of a single type of
mature plasma cell and, indeed, is the source of homoge-
neous myeloma immunoglobulins, the structural analysis of
which has led to many of the generalizations outlined above.
A special form of multiple myeloma is beginning to pro-
vide new insights into the differentiation process of B cells.
Occasionally, individuals with multiple myeloma synthesize
large quantities of two distinct myeloma immunoglobulins.
Serological and chemical studies on the best-studied example
of biclonal myeloma proteins from the human patient, Til,
suggest that the light chains and VH regions in the IgM and
IgG myeloma proteins are very similar, if not identical (6-
9). These molecular observations, together with those from a
variety of cellular studies, suggest that a B lymphocyte ini-
tially has IgM receptors and that, in the course of differen-
tiation, subclones arise which synthesize IgG molecules with
precisely the same specificity. That is, the light chain ex-
pressed in this clone of antibody-producing cells remains the
same throughout the differentiation process while the VH
gene is expressed first in association with a C,, gene (IgM)
and then in association with a C, gene (IgG). Thus, a funda-
mental aspect of differentiation in B cells is the association
of one VH gene with two or more CH genes.
Preliminary reports have indicated that IgA and IgG im-
munoglobulins from patients with biclonal myeloma pro-
teins also have similar light chains and VH regions (10-12).
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Prototype V,,1 Asp-lle-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-Ser-Val-Gly-Asp-Arg-Val-Thr
IgG V, Thr
IgA V, Thr
30 40
Prototype V,,, lle-Thr-Cys-Arg-Ala-Ser-Gln-Ser-lle-Ser-HYP-Trp-Leu-Asn-Trp-Tyr-Gln-Gln-Lys-Pro
IgG V,, Arg Ser Ala Arg
IgA V, Arg Ser Ala Arg
HVI
FIG. 1. The NH2-terminal amino-acid sequences of V,, regions from biclonal immunoglobulins of the human patient GR. These se-
quences are compared with a prototype sequence of the human V, subgroup I (17). Boxes indicate residues not previously seen in other
human V,, regions. HYP indicates a prototype position with many residue alternatives (hypervariable). HVI indicates the extent of the first
hypervariable region. The amide-acid distinctions have not been determined.
This study analyzes the amino-acid sequences of the light
and heavy chains derived from IgG and IgA immunoglobu-
lins from the biclonal patient, GR, through the first hyper-
variable regions.
MATERIALS AND METHODS
Techniques for the isolation and chain separation of biclonal
immunoglobulins have been described (13). Each chain was
subjected to 40-45 steps of automated Edman degradation
on Beckman 890A protein sequenator (14). Yields of ap-
proximately 50% were noted at step 1, and the repetitive
yields averaged 90% for all chains.
RESULTS
Variable Regions of GR Biclonal Immunoglobulins Ap-
pear to Be Very Similar and Possibly Identical to One An-
other. The VK regions from the IgA and IgG proteins are
identical over their NH2-terminal 40 residues (Fig. 1). The
unique relationship of these light chains is emphasized by
the fact they share two residues (i.e., positions 27 and 39)
never before seen in more than 80 human VK sequences (15,
16) and have identical first hypervariable regions. Further-
more, amino-acid analyses, comparisons of chromatograms
in three different systems, electrophoretic mobilities in five
different systems, and isoelectric focusing are all consistent
with the identity of these two light chains (13). Accordingly,
this evidence strongly supports the identity of the light
chains from the GR IgA and IgG immunoglobulins.
The VH regions from the GR biclonal proteins are identi-
cal over their NHg-terminal 45 residues (Fig. 2). The identi-
ty of these VH regions throughout the extremely diverse first
hypervariable region, as well as the observation that three
residues are shared by these VH regions that have not pre-
viously been seen in more than 25 human VH regions (i.e.,
residues 33, 38, and 43), suggest that these VH regions are
uniquely related and very similar if not identical to one an-
other (15, 17, 20). Supporting this supposition is the fact that
both the IgA and IgG proteins from GR share their individu-
al antigenic determinants (12).
Caution, however, must be used in attempts to extrapolate
V region identity from partial amino-acid sequence data.
Examples are known in which heavy chains identical
through the first hypervariable region have residue differ-
ences at later positions in the variable region (see Fig. 7 in
ref. 1). Indeed, the amino-acid sequence data from biclonal
immunoglobulins accumulated to date on the presumptive
identity of VH regions are surprisingly meager (11, 18).
Even with the immunoglobulins of the most thoroughly
studied biclonal patient, Til, the sequences of the first and
last hypervariable regions of the y and IA heavy chains were
not completely determined (compare the VH sequences in
refs. 7 and 17), and no sequence data are available for the
second hypervariable region. Thus, apart from this study,
the sequences of no active-site associated hypervariable re-
gions have been completely determined in the VH regions of
a biclonal pair.
With the reservations above noted, we conclude that simi-
lar, if not identical, VH regions can be associated with bicl-
nal IgA and IgG immunoglobulins containing similar and
probably identical light chains.
Our Study and Various Others Are Consistent with the
Supposition That a Single VH Gene Is Associated with
Two or More CH Genes During Differentiation of Anti-
body-Producing Cells. (i) The normal immune response
undergoes a maturational process in which the predominant
antibody type shifts from IgM to IgG (C,,- Ca) while re-
taining antigenic specificity. This implies that the same V
regions are associated with different immunoglobulin
classes. (ii) Antisera directed against the variable regions of
specific antibodies (i.e., antiidiotype antisera) demonstrate
10 20
Prototype VHIII Glu-Val-Gln-Leu-Val-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Leu-Arg-Leu-Ser-Cys-Ala-
lgG VH
IgA VH
30 40
Prototype VHIII Ala-Ser-Gly-Phe-Thr-Phe-Ser-Thr-HYP-HYP-HYP-HYP-Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu
IgG VH Ala-Asx T Met-( Pro Arg
IgA VH Ala-Asx jTyr-Met -( ) Pro Arg
HV,
FIG. 2. The NH2-terminal amino-acid sequences of VH regions from biclonal immunoglobulins of the human patient GR. These se-
quences are compared with a prototype sequence of the human VH subgroup III (20). The amide-acid distinctions have not been determined.
Parentheses indicate an unidentified residue. See legend to Fig. 1.
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FIG. 3. Two models for the association of a VH gene to multiple CH genes. (a) The simultaneous insertional model. (b) The successive in-
sertional model (see text).
that the IgM and IgG classes of antibodies in a given im-
mune response may share V region idiotypes (i.e., V se-
quences) (19). (iii) Single lymphocytes may synthesize two
or more classes of immunoglobulins. For example, adult and
neonatal lymphocytes have both IgM and IgD on their cell
surfaces (20-23). The identity of antigenic specificity (24,
25), allotype (26), or idiotype (27) in pairs of immunoglobu-
lins produced by a single lymphocyte once again suggests
the same V regions are associated with different C regions.
(iv) A single lymphocyte may produce daughter cells that
synthesize immunoglobulins of differing class while main-
taining antigenic specificity and idiotype (28). (v) The treat-
ment of lymphoid cells with anti-A chain antisera early in
development inhibits the production of IgG and IgA anti-
body-forming cells (29-S1). This suggests that there is an or-
derly differentiation process and that IgG and IgA cells are
derived from IgM precursors (32-34). (vi) Chemical and
serological studies have suggested that identical VH regions
can be shared by two myeloma proteins derived from a pa-
tient with biclonal myeloma (ref. 7 and this study).
Two controversial questions arise from the association of
one VH region with multiple CH regions. First, is the associa-
tion of one VH gene with multiple CH genes a differentia-
tion process that is antigen driven? Clearly the simultaneous
expression of IgM and IgD on mouse lymphocytes is antigen
independent (35). Other studies suggest the "switch" of cer-
tain immunoglobulin classes may be antigen driven (30, 33).
Thus, certain "switches" are antigen independent whereas
others may be antigen dependent. Second, is there a linear
pathway of differentiation (e.g., IgM -m IgD - IgG m IgA)
or may IgM cells differentiate directly to produce any of the
other immunoglobulin classes? The suppression of all immu-
noglobulin classes by the treatment of embryos with anti-A
antiserum suggests that IgM cells are the precursors to all
other immunoglobulin-producing cells (29-31). Beyond this,
very few conclusions can be drawn (see refs. 30, 32, and 33).
Two General Models May Account for Association of a
Single VH Gene with Two or More CH Genes. First, the VH
gene may be copied many times over and separate copies bejoined to each CH gene in the heavy chain family (Fig. 3,
model a). The differentiation process would then consist of
the successive activation of complete VH-CH genes by con-
ventional mechanisms of gene regulation (36). We have
termed this the simultaneous insertional model. Second, a
single VH gene could, as others have postulated (9), "switch"
from one CH gene to a second (or even a third) during the
differentiation process. Accordingly, each cell could only
transcribe a single VH-CH gene at a particular point in time
(Fig. 3, model b). We have termed this the successive inser-
tional model. Although most immunologists have thought
about the V-C joining process primarily in terms of the suc-
cessive insertional model (9), some recent observations are
consistent only with the simultaneous insertional model. The
clear demonstration that a single antibody-producing cell
can synthesize two or more classes of immunoglobulin with
the same V regions over a long period of time (longer than
the lifetime of H chain mRNA) would eliminate the succes-
sive insertional model because according to this model only
a single VH-CH gene combination can be transcribed at any
point in time. Three observations suggest a single antibody-
producing cell can synthesize two immunoglobulin classes si-
multaneously. First, a patient with chronic lymphocytic leu-
kemia has a monoclonal IgM that exhibits an anti-IgG activi-
ty (i.e., rheumatoid activity). This patient's leukemic lym-
phocytes exhibit IgD and IgM on their surface that can be
cocapped with aggregated IgG (37). Accordingly, the speci-
ficity of the IgD and IgM molecules appears to be identical.
Second, the idiotype of IgM and IgD molecules found on the
majority of peripheral B lymphocytes in a patient with
chronic lymphocytic leukemia and macroglobulinemia is the
same (27). This suggests the variable regions of the two mol-
ecules are very similar, if not identical. Finally, a mouse
myeloma tumor, TEPC 609, has been cloned in which single
cells synthesize IgG2b and IgA molecules. These molecules
have the same idiotype (H. C. Morse, III, personal commu-
nication). These studies demonstrate that a single cell can
synthesize two classes of immunoglobulins over an extended
period of time. Furthermore, the V regions produced by
each cell are very similar, if not identical, by specificity or
idiotype analysis. These data support the simultaneous inser-
tional model. Two types of studies might unequivocally veri-
fy this model. First, the demonstration that a single cell can
synthesize two or more classes of immunoglobulin with V re-
gions of identical amino-acid sequence would be compelling
evidence for the simultaneous insertional model. Second,
perhaps nucleic acid hybridization or reassociation experi-
Immunology: Sledge et al.
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ments in the future may be able to differentiate between
one or two VH genes (successive insertional model) and ten
or more VH genes (simultaneous insertional model).
A variety of specific V-C joining mechanisms have been
proposed (see ref. 38). The "copy-splice" model suggests
that a given V gene may be copied and spliced onto one or
more C genes (39). The "episomal" model suggests that a V
gene may be converted into an episome and then reintegrat-
ed back into the genome adjacent to one or more CH genes
(40). The "looping out" model suggests that a V gene may
be joined to a C gene by deleting as a circle all the interven-
ing DNA. When this same V gene is joined to a new C gene,
once again the intervening genetic material is lost as a circle
(2, 41). Thus, a "looping out" process would successively join
a V gene with different C genes. Finally, the "lateral gene
duplication" model suggests a branching network of V and
C genes which simultaneously places every VH gene adja-
cent to every CH gene (42). Control switches would then de-
termine which VH-CH combination was transcribed. The
first two mechanisms are compatible with either of the mod-
els described in the preceding paragraph, whereas the latter
two are only possible with the successive insertional model.
Because of the observations discussed in the preceding para-
graph, one of the first two mechanisms appears more likely.
In the Biclonal Patient, GR, the Myeloma Process Prob-
ably Transformed a Precursor Lymphocyte That Synthesi-
zes or Produces Daughter Cells Synthesizing Different
Classes of Immunoglobulin. A number of observations
suggest that the biclonal myeloma process generally trans-
forms a single lymphocyte. In this regard the statistics of the
myeloma process are interesting. Multiple myeloma occurs
spontaneously in man with a frequency of approximately
1/20,000 individuals (43). If the biclonal myelomas were
produced by two independent transformations, about
1/20,000 patients with multiple myeloma should exhibit two
myeloma proteins. However, in extensive case study, about
1% of the individuals with multiple myeloma expressed two
distinct immunoglobulins (44). The relative abundance of
biclonal myeloma proteins is most easily explained by postu-
lating that in about 1% of the myeloma cases, a precursor
cell is transformed that expresses two immunoglobulins or is
capable of differentiating into daughter clones that express
different classes of immunoglobulins. This supposition is also
consistent with the observation that the light chains and VH
regions in the few well-studied biclonal examples appear to
be similar, if not identical (ref. 7 and this study).
At Least Three General Categories of Biclonal Proteins
Exist, Each with Different Genetic and Developmental
Implications. One category is the multiclonal IgM proteins
produced by Waldenstrom's macroglobulinemia at a surpris-
ingly high frequency (about 10%) (45, 46). The C regions of
these immunoglobulins appear to be identical, whereas the
V regions for one chain (light or heavy) are different while
those for the second chain are similar. This category of biclo-
nal proteins is consistent with the supposition that a single
clone of cells selects a particular combination of VH and VL
genes to be expressed as an IgM molecule. Subsequently, a
subclone may be produced that expresses the same VL (or
VH) region while shifting to the expression of a new VH (or
VL) region. The new V region expressed might result from
somatic mutation or the expression of new germ line genes.
In the two best studied cases, the presence of multiple
amino-acid differences renders somatic mutation less likely
antibody-producing cells, a diversity of antibody receptors
(clones) may be generated by the combinatorial association
of one VL region with multiple VH regions (or vice versa).
Whether the readout of this information is programmed or
random is an issue of enormous importance to developmen-
tal biology. Unfortunately, very little amino-acid sequence
analysis has been carried out on proteins of this category
(46).
In the second category, the light chains and VH regions of
both proteins appear identical, whereas the CH regions are
different. Biclonal proteins of this class, such as the GR im-
munoglobulins described in this paper, suggest that during
the normal development of an antibody-producing cell the
VH gene is joined with many CH genes which allows the cor-
responding cell or its clonal descendents to express two (or
more) classes of immunoglobulins (refs. 9, 11, 22, and this
study). Since it appears generally that two distinct clones
produce these proteins (44), it is postulated that each clone
represents a distinct stage of this differentiation process. Ac-
cordingly, these pairs of proteins may shed insight into the
order and nature of the molecular switching events.
The third category of biclonal proteins comprises those
which include pairs with apparently unrelated chains (e.g., X
and K chains). This category may result from two indepen-
dent neoplastic transformations. Little serological or se-
quence information is available on proteins of this category.
The different categories of biclonal proteins may also rep-
resent different stages in the development of antibody-pro-
ducing cells. Perhaps the first category reflects the process of
diversity generation in precursor IgM cells, whereas the sec-
ond category reflects the subsequent differentiation of an
IgM cell with a particular VH-VL combination into daughter
cells capable of expressing the same active site (VH-VL) in
association with other immunoglobulin classes. Too little in-
formation is available on proteins of the third category to
speculate on their relationship, if any, to the differentiation
process in antibody-producing cells.
As indicated above, the biclonal proteins may provide im-
portant insights into the process of antibody differentiation.
However, before detailed conclusions can be reached, a
large number of biclonal pairs must be studied with regard
to three vital questions. (i) Into which of the three general
categories do the biclonal proteins fall? Each category has
very different developmental implications. (ii) Are the V re-
gions in the appropriate chain (category 1) or chains (cate-
gory 2) actually identical? If even a few substitutions are
found, the significance of these proteins could change ac-
cording to one's view of antibody diversity. (iii) Are the bi-
clonal immunoglobulins produced by a single clone or by
two clones of cells? This has, for example, important impli-
cations for the mechanism of VH-CH joining.
Biclonal immunoglobulin proteins have recently been de-
tected among the myeloma tumor products of two inbred
strains of mice, BALB/c and NZB (H. C. Morse, III, personal
communication; M. Weigert, personal communication).
These systems will offer many advantages over the human
system for analysis of the developmental implications of
these molecular curiosities.
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